{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:04:54Z","timestamp":1785369894081,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ram\u00f3n y Cajal Institute of Health Research"},{"name":"Ram\u00f3n y Cajal University Hospital and funded publicly"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>BRCA1\/2 genes play a critical role in genome stability and DNA repair. In animal models, loss of cardiomyocyte-specific BRCA1\/2 is associated with DNA damage, apoptosis, cardiac dysfunction, and mortality following anthracycline exposure. However, whether these preclinical findings translate to humans remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Assess the impact of germline BRCA1\/2 (gBRCA1\/2) status on anthracyclines-induced cardiotoxicity (AIC) in patients with early breast cancer and no prior anti-HER2 therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-center retrospective\/prospective cohort study focused on early breast cancer patients, treated with anthracycline-based chemotherapy in the neo\/adjuvant setting, no prior anti-HER2 therapy, and known gBRCA1\/2 status, normal baseline left ventricular ejection fraction (LVEF), and no previous cardiovascular disease. Follow-up assessments involved myocardial dysfunction blood biomarkers (MDBB), transthoracic echocardiography (TTE), and quality of life (QoL) questionnaires. The primary objective was LVEF changes comparing BRCA1\/2 mutation carriers (gBRCA1\/2m) vs non-carriers (gBRCA1\/2wt). Secondary objectives included differences in MDBB and QoL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 137 patients were included (103 gBRCA1\/2wt and 34 gBRCA1\/2m). Baseline characteristics were similar between groups. Compared to baseline, LVEF% reduction was \u22124.7[\u221212.0, 0.0] vs \u22129.5[\u221218.0, \u22125.0] in gBRCA1\/2wt vs gBRCA1\/2m, (P\u2005=\u2005.027). After adjusting for confounders, the difference in reduction in LVEF remained statistically significant at \u22124.5 [95%CI, \u22128.6, \u22120.4; P\u2005=\u2005.032]. No differences between MDBB (C-reactive protein, hsTnI, NT-proBNP, D-Dimer, ST-2, or Galectine-3) or QoL (MLHFQ and EQ5-D index) were detected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>gBRCA1\/2m patients could represent a higher-risk population for AIC. gBRCA1\/2 status should be one of the factors to consider in deciding on adjuvant anthracycline necessity. This population could benefit from a cardio-oncology closer follow-up and cardioprotective strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae299","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T13:13:07Z","timestamp":1732021987000},"source":"Crossref","is-referenced-by-count":3,"title":["Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1\/2 mutation: the BRCAN study"],"prefix":"10.1093","volume":"30","author":[{"given":"Alfonso","family":"Cort\u00e9s-Salgado","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Serrano","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Grupo Vithas Madrid , 28043 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cordero Pereda","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Menacho","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Del Rey","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"del Campo-Albendea","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS). CIBERESP , ISCIII, 28029 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Saavedra","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Chamorro","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Rosero","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Sotoca","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Guill\u00e9n-Ponce","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Guerra","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Fern\u00e1ndez-Abad","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"L\u00f3pez-Miranda","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Mart\u00ednez-J\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gion","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Salazar","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Agudo-Qu\u00edlez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Garrido","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS) , 28034\u00a0Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo Luis","family":"Alonso Salinas","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitario de Navarra , 31008\u00a0Pamplona (Navarra) ,","place":["Spain"]},{"name":"Navarrabiomed, IdiSNA , 31008\u00a0Pamplona (Navarra) ,","place":["Spain"]},{"name":"Universidad P\u00fablica de Navarra (UPNA) Department of Health Sciences, , 31008\u00a0Pamplona (Navarra) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"2025082923462743400_CIT0001","volume-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2024"},{"key":"2025082923462743400_CIT0002","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1007\/s12094-023-03215-4","article-title":"SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)","volume":"25","author":"Ayala de la Pe\u00f1a","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"2025082923462743400_CIT0003","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"key":"2025082923462743400_CIT0004","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","article-title":"The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Omland","year":"2022","journal-title":"JACC CardioOncology"},{"key":"2025082923462743400_CIT0005","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2025082923462743400_CIT0006","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart (British Cardiac Society)"},{"key":"2025082923462743400_CIT0007","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2025082923462743400_CIT0008","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1200\/JCO.18.02050","article-title":"Moving From Poly (ADP-Ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy","volume":"37","author":"Gourley","year":"2019","journal-title":"J. Clin. Oncol"},{"key":"2025082923462743400_CIT0009","doi-asserted-by":"publisher","first-page":"6604","DOI":"10.1074\/jbc.M111.292664","article-title":"BRCA2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure","volume":"287","author":"Singh","year":"2012","journal-title":"J Biol Chem"},{"key":"2025082923462743400_CIT0010","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/ncomms1601","article-title":"BRCA1 is an essential regulator of heart function and survival following myocardial infarction","volume":"2","author":"Shukla","year":"2011","journal-title":"Nat Commun"},{"key":"2025082923462743400_CIT0011","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10549-016-3678-2","article-title":"Cardiac function in BRCA1\/2 mutation carriers with history of breast cancer treated with anthracyclines","volume":"155","author":"Barac","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2025082923462743400_CIT0012","doi-asserted-by":"publisher","first-page":"833171","DOI":"10.3389\/fcvm.2022.833171","article-title":"BRCA1\/2 mutations and cardiovascular function in breast cancer survivors","volume":"9","author":"Demissei","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025082923462743400_CIT0013","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10549-016-4101-8","article-title":"The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy","volume":"162","author":"Pearson","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2025082923462743400_CIT0014","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s12094-015-1435-3","article-title":"SEOM clinical guidelines in hereditary breast and ovarian cancer","volume":"17","author":"Llort","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"2025082923462743400_CIT0015","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12094-019-02262-0","article-title":"SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)","volume":"22","author":"Gonz\u00e1lez-Santiago","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"2025082923462743400_CIT0016","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2025082923462743400_CIT0017","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/ejechocard\/jen174","article-title":"European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies","volume":"9","author":"Evangelista","year":"2008","journal-title":"Eur J Echocardiogr"},{"key":"2025082923462743400_CIT0018","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"Association","year":"2013","journal-title":"JAMA"},{"key":"2025082923462743400_CIT0019","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/S2468-2667(19)30155-0","article-title":"Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data","volume":"4","author":"Zhu","year":"2019","journal-title":"Lancet Public Health"},{"key":"2025082923462743400_CIT0020","doi-asserted-by":"publisher","first-page":"102196","DOI":"10.1016\/j.esmoop.2023.102196","article-title":"Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD)","volume":"9","author":"Incorvaia","year":"2024","journal-title":"ESMO Open"},{"key":"2025082923462743400_CIT0021","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/genes8020059","article-title":"An exploratory study to determine whether BRCA1 and BRCA2 mutation carriers have higher risk of cardiac toxicity","volume":"8","author":"Sajjad","year":"2017","journal-title":"Genes"},{"key":"2025082923462743400_CIT0022","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jacc.2007.05.014","article-title":"Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study","volume":"50","author":"Januzzi","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2025082923462743400_CIT0023","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1161\/01.CIR.0000127958.21003.5A","article-title":"Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction","volume":"109","author":"Shimpo","year":"2004","journal-title":"Circulation"},{"key":"2025082923462743400_CIT0024","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1590\/s0066-782x2011005000058","article-title":"Growth-differentiation factor-15: a novel biomarker in patients with diastolic dysfunction","volume":"97","author":"Dinh","year":"2011","journal-title":"Arq Bras Cardiol"},{"key":"2025082923462743400_CIT0025","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00392-010-0125-y","article-title":"Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study","volume":"99","author":"Lok","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"2025082923462743400_CIT0026","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2025082923462743400_CIT0027","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology","volume":"4","author":"Porter","year":"2022","journal-title":"JACC CardioOncology"},{"key":"2025082923462743400_CIT0028","doi-asserted-by":"publisher","first-page":"10323","DOI":"10.1007\/s00520-022-07368-w","article-title":"Effect of aerobic exercise on cardiotoxic outcomes in women with breast cancer undergoing anthracycline or trastuzumab treatment: a systematic review and meta-analysis","volume":"30","author":"Ma","year":"2022","journal-title":"Support Care Cancer"},{"key":"2025082923462743400_CIT0029","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy","volume":"266","author":"Steinherz","year":"1991","journal-title":"JAMA"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae299\/60751667\/oyae299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae299\/60751667\/oyae299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T03:46:35Z","timestamp":1756525595000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae299\/7904824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae299","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2024,11,19]]},"article-number":"oyae299"}}